Author:
Cheung Carol C.,Smith Adam C.,Albadine Roula,Bigras Gilbert,Bojarski Anna,Couture Christian,Cutz Jean-Claude,Huang Weei-Yuan,Ionescu Diana,Itani Doha,Izevbaye Iyare,Karsan Aly,Kelly Margaret M.,Knoll Joan,Kwan Keith,Nasr Michel R.,Qing Gefei,Rashid-Kolvear Fariboz,Sekhon Harmanjatinder S.,Spatz Alan,Stockley Tracy,Tran-Thanh Danh,Tucker Tracy,Waghray Ranjit,Wang Hangjun,Xu Zhaolin,Yatabe Yasushi,Torlakovic Emina E.,Tsao Ming-Sound
Subject
Cancer Research,Pulmonary and Respiratory Medicine,Oncology
Reference35 articles.
1. ROS1 rearrangements define a unique molecular class of lung cancers;Bergethon;J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol.,2012
2. Research C for DE and. FDA Approves Crizotinib Capsules. FDA 2019. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-crizotinib-capsules. Accessed January 30, 2021.
3. Crizotinib in ROS1-rearranged non-small-cell lung cancer;Shaw;N Engl. J. Med.,2014
4. FDA Center for Drug Evaluation and Research. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC. FDA 2019. Available at: http://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc. Accessed December 31, 2019.
5. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献